deltatrials
Active Not Recruiting INTERVENTIONAL NCT02466737

Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary Surgery (INSEMA)

Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary Surgery in Patients With Early-stage Invasive Breast Cancer and Breast-conserving Surgery: a Randomized Prospective Surgical Trial. Intergroup-Sentinel-Mamma (INSEMA)-Trial

Sponsor: GBG Forschungs GmbH

Conditions Breast Cancer
Updated 19 times since 2017 Last updated: Apr 30, 2026 Started: Sep 1, 2015 Primary completion: Aug 30, 2024 Completion: Dec 1, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02466737, this observational or N/A phase trial focuses on Breast Cancer and remains ongoing. Sponsored by GBG Forschungs GmbH, it has been updated 19 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Study Description(click to expand)

Currently, axillary surgery for breast cancer is considered as staging procedure that does not seem to influence breast cancer mortality, since the risk of developing metastasis depends mainly on the biological behaviour of the primary (seed-and-soil model). Based on this, the postsurgical therapy should be considered on the basis of biologic tumor characteristics rather than nodal involvement. The goal of the present study is to show that early-stage breast cancer patients with reduced extent of axillary surgery are not inferior regarding disease-free survival outcome compared with the standard arm. All patients will be first randomized to either no axillary surgical intervention or axillary sentinel lymph node biopsy (SLNB). Patients with SLNB and pN+(sn) status will be secondly randomized to either SLNB alone or completion axillary lymph node dissection (ALND) in cases with less than four involved nodes (1-3 macrometastases). Patients with four or more metastatic sentinel lymph nodes should undergo completion ALND. Postoperative systemic treatment should be based on local multidisciplinary tumor board recommendation according to the current German AGO and S3 guidelines. For women who are treated with breast-conserving surgery, the most common site of local recurrence is the conserved ipsilateral breast itself. Thus, whole-breast radiation therapy after breast-conserving...

Currently, axillary surgery for breast cancer is considered as staging procedure that does not seem to influence breast cancer mortality, since the risk of developing metastasis depends mainly on the biological behaviour of the primary (seed-and-soil model). Based on this, the postsurgical therapy should be considered on the basis of biologic tumor characteristics rather than nodal involvement.

The goal of the present study is to show that early-stage breast cancer patients with reduced extent of axillary surgery are not inferior regarding disease-free survival outcome compared with the standard arm. All patients will be first randomized to either no axillary surgical intervention or axillary sentinel lymph node biopsy (SLNB). Patients with SLNB and pN+(sn) status will be secondly randomized to either SLNB alone or completion axillary lymph node dissection (ALND) in cases with less than four involved nodes (1-3 macrometastases). Patients with four or more metastatic sentinel lymph nodes should undergo completion ALND.

Postoperative systemic treatment should be based on local multidisciplinary tumor board recommendation according to the current German AGO and S3 guidelines. For women who are treated with breast-conserving surgery, the most common site of local recurrence is the conserved ipsilateral breast itself. Thus, whole-breast radiation therapy after breast-conserving surgery is mandatory and should be performed according to the current guidelines (S3, AGO, DEGRO).

During follow-up, patients will be assessed for disease recurrence according to standard clinical practice. History and physical examination will be performed every 6 months for the first 36 months and yearly thereafter. Annual mammography and sonography will be required; other testing will be based on symptoms and investigator preference. The total number of patients to be randomized into the trial will be approximately 7,095. An event-driven final efficacy analysis will be performed per-protocol for two primary objectives.

Status Flow

~Jan 2017 – ~Jun 2017 · 5 months · monthly snapshot~Jun 2017 – ~Oct 2017 · 4 months · monthly snapshot~Oct 2017 – ~May 2018 · 7 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshot~Feb 2019 – ~Jun 2019 · 4 months · monthly snapshot~Jun 2019 – ~Dec 2020 · 18 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~May 2022 · 16 months · monthly snapshot~May 2022 – ~Jan 2023 · 8 months · monthly snapshot~Jan 2023 – ~Jun 2024 · 17 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – ~Apr 2025 · 3 months · monthly snapshot~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshot~Sep 2025 – ~May 2026 · 8 months · monthly snapshotMay 4, 2026 – present · 3 months · daily API

Change History

19 versions recorded
  1. May 4, 2026 — Present [daily]

    Active Not Recruiting

    Phase: NANone

  2. Sep 2025 — May 2026 [monthly]

    Active Not Recruiting NA

  3. Apr 2025 — Sep 2025 [monthly]

    Active Not Recruiting NA

  4. Jan 2025 — Apr 2025 [monthly]

    Active Not Recruiting NA

  5. Sep 2024 — Jan 2025 [monthly]

    Active Not Recruiting NA

Show 14 earlier versions
  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting NA

  2. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting NA

  3. Jan 2023 — Jun 2024 [monthly]

    Active Not Recruiting NA

  4. May 2022 — Jan 2023 [monthly]

    Active Not Recruiting NA

  5. Jan 2021 — May 2022 [monthly]

    Active Not Recruiting NA

  6. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting NA

  7. Jun 2019 — Dec 2020 [monthly]

    Active Not Recruiting NA

    Status: RecruitingActive Not Recruiting

  8. Feb 2019 — Jun 2019 [monthly]

    Recruiting NA

  9. Nov 2018 — Feb 2019 [monthly]

    Recruiting NA

  10. Jun 2018 — Nov 2018 [monthly]

    Recruiting NA

  11. May 2018 — Jun 2018 [monthly]

    Recruiting NA

  12. Oct 2017 — May 2018 [monthly]

    Recruiting NA

  13. Jun 2017 — Oct 2017 [monthly]

    Recruiting NA

  14. Jan 2017 — Jun 2017 [monthly]

    Recruiting NA

    First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

Although there is no doubt that the presence of lymph node metastases worsens prognosis of a patient, unambiguous evidence to support lymph node dissection is still lacking. For many solid tumors, the role of lymph node dissection is yet controversial, and may depend on the tumor type and the stage of patient presentation for diagnosis. Axillary surgery for breast cancer is now considered as staging procedure that does not seem to influence breast cancer mortality. Women with breast cancer have benefitted greatly from a series of carefully performed randomized controlled trial focusing on axillary surgery. The objective of INSEMA is to show that less axillary surgery is better, in that oncological outcomes are the same and less surgical intervention will result in fewer surgical complications.

Contact Information

Sponsor contact:
  • GBG Forschungs GmbH
  • German Cancer Aid
  • University of Rostock
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .